Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Focusing on the unmet medical needs of patients with rare disorders and their families

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

03.11

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights

03.07

Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

02.26

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol

02.20

Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors